In 2008, I started one of the first Precision Medicine companies. N-of-One was inspired by my deep interest in cancer drug development and diagnostics and borne out of my work with pharma and biotech, combined with efforts to help multiple friends and family members navigate their fight against bad cancer.

We started as a high-touch service. There were so many heartbreaking stories and incredible outcomes that drove us to become the world leaders in Molecular Oncology Decision Support. The N-of-One Solution is still the backbone of NGS labs and hospital systems, creating treatment strategies for hundreds of thousands of patients globally.

The N-of-One journey taught us many lessons that inspired me to start a clinical trials company.

More recently, my work with the Blue Venture Fund has been immensely valuable in understanding the payer priorities and their commitment to high-quality care. Payers are critical stakeholders in solving the massive problems we have with unsustainably rising drug costs and lack of access to cutting-edge care, even for those of us who are lucky enough to have access and resources. But they cannot solve this problem alone.

Through this work and much more in cancer and rare diseases, we are inspired to start Medzown. We have been fortunate to develop a deep, close network of thought leaders spanning the many key precision medicine stakeholders who want to come together through Medzown to solve the immense challenges of getting patients the right diagnosis and treatments at the right time, place and, importantly, at the right cost!

The system is broken. We must act with urgency. We want and need to solve this challenge, so we can build a sustainable healthcare system and better care for the ones we love. Please join us on this journey!